irinotecan has been researched along with Neoplasm Metastasis, Unknown Primary in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Afchain, P; Baudin, E; Desgrippes, R; Hadoux, J; Hautefeuille, V; Lepage, C; Lorgis, V; Monterymard, C; Scoazec, JY; Thuillier, F; Tougeron, D; Walter, T | 1 |
| Boilève, A; De Lonlay, P; Ducreux, M; Hollebecque, A; Jozwiak, M; Leroy, F; Malka, D; Ottolenghi, C; Pontoizeau, C; Verret, B; Wicker, C | 1 |
| Aoki, T; Chono, T; Hyuga, S; Kobayashi, K; Matsumoto, T; Moon, JH; Nishioka, K; Takachi, K; Takemoto, H; Tsukao, Y; Uemura, Y; Watanabe, R | 1 |
| Chohnabayashi, N; Ishikawa, G; Jinta, T; Kitamura, A; Mochizuki, S; Nishimura, N; Suzuki, K; Tomishima, Y; Yamano, Y | 1 |
| Antoniotti, C; Battaglin, F; Berenato, R; Bergamo, F; Borelli, B; Caporale, M; Cremolini, C; De Braud, F; Falcone, A; Fontanini, G; Lonardi, S; Loupakis, F; Marmorino, F; Marsico, VA; Masi, G; Mennitto, A; Moretto, R; Pietrantonio, F; Rossini, D; Salvatore, L | 1 |
| Ando, M; Arioka, H; Fujiwara, Y; Hirakawa, A; Hirata, T; Katsumata, N; Kouno, T; Matsumoto, K; Shimizu, C; Tamura, K; Yamanaka, Y; Yonemori, K; Yunokawa, M | 1 |
| Ando, M; Fujiwara, Y; Hirata, T; Katsumata, N; Ono, M; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K | 1 |
| Ames, MM; Behrens, RJ; Erlichman, C; Foster, NR; Goetz, MP; Graham, DL; Holtan, SG; Medeiros, F; Safgren, SL; Steen, PD | 1 |
| Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA | 1 |
| Allouache, J; Bouzy, J; Bugat, R; Coudert, B; Culine, S; Douillard, JY; Fizazi, K; Goupil, A; Kaminsky, MC; Laplanche, A; Lesimple, T; Lortholary, A; Merrouche, Y; Négrier, S; Petrow, P; Pivot, X; Priou, F; Théodore, C; Viala, J; Voigt, JJ | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hermann, R; Litchy, S; Morrissey, LH; Rodriguez, GI; Shaffer, DW; Yardley, DA | 1 |
| Greco, FA; Hainsworth, JD; Kommor, M; Kuzur, ME; Litchy, S; Raefsky, EL; Spigel, DR; Yost, K | 1 |
| Komatsu, N; Makuuchi, H; Matsui, N; Mukai, M; Nakamura, M; Nakasaki, H; Ninomiya, H; Sato, S; Wakui, K | 2 |
| Aravantinos, G; Bamias, A; Briasoulis, E; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Makatsoris, T; Mylonakis, N; Papakostas, P; Pavlidis, N; Samantas, E; Skarlos, D; Varthalitis, I; Xiros, N | 1 |
8 trial(s) available for irinotecan and Neoplasm Metastasis, Unknown Primary
| Article | Year |
|---|---|
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Neuroendocrine; Etoposide; Female; Fluorouracil; Humans; Intestinal Neoplasms; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Progression-Free Survival; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2021 |
Irinotecan plus carboplatin for patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Survival Rate | 2009 |
Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Treatment Outcome | 2012 |
Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Vomiting | 2002 |
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary | 2003 |
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2004 |
Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Survival Analysis; Treatment Outcome | 2005 |
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Organoplatinum Compounds; Oxaliplatin | 2008 |
7 other study(ies) available for irinotecan and Neoplasm Metastasis, Unknown Primary
| Article | Year |
|---|---|
5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Diseases; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Hyperammonemia; Irinotecan; Leucovorin; Neoplasms, Unknown Primary; Oxaliplatin; Prognosis; Retreatment | 2019 |
[Long-term survival after surgical resection of a cancer of unknown primary site-a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Neoplasms, Unknown Primary; Oxonic Acid; Tegafur; Time Factors | 2013 |
Long-term survival of a patient with extensive small cell carcinoma of unknown primary etiology complicated by nephrotic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Edema; Etoposide; Glomerulonephritis, Membranous; Humans; Irinotecan; Lymphatic Metastasis; Neoplasms, Unknown Primary; Nephrotic Syndrome; Paraneoplastic Syndromes; Pleural Effusion, Malignant; Proteinuria; Radiotherapy, Adjuvant; Remission Induction; Tomography, X-Ray Computed | 2014 |
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; GTP Phosphohydrolases; Humans; Irinotecan; Male; Membrane Proteins; Middle Aged; Mutation; Neoplasms, Unknown Primary; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras) | 2016 |
Second-line chemotherapy in patients with primary unknown cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2011 |
Sensitivity to CPT-11 and platinum derivatives of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.
Topics: bcl-2-Associated X Protein; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Humans; Immunohistochemistry; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Unknown Primary; Organoplatinum Compounds; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors | 2007 |
Sensitivity to CPT-11 and platinum derivatives of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses.
Topics: bcl-2-Associated X Protein; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Humans; Immunohistochemistry; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Unknown Primary; Organoplatinum Compounds; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors | 2007 |